Loading...
Crescita Therapeutics Inc.
CTX.TO•TSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.47
CA$0.00(0.00%)
Crescita Therapeutics Inc. (CTX.TO) Financial Performance & Income Statement Overview
Review Crescita Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
11.75%
↑ 11.75%
Operating Income Growth
-64.37%
↓ 64.37%
Net Income Growth
-38.47%
↓ 38.47%
Operating Cash Flow Growth
31.26%
↑ 31.26%
Operating Margin
-19.57%
↓ 19.57%
Gross Margin
49.36%
↑ 49.36%
Net Profit Margin
-16.86%
↓ 16.86%
ROE
-19.11%
↓ 19.11%
ROIC
-23.36%
↓ 23.36%
Crescita Therapeutics Inc. (CTX.TO) Income Statement & Financial Overview
Review Crescita Therapeutics Inc.'s (CTX.TO) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $6.90M | $3.59M | $4.09M | $5.00M |
| Cost of Revenue | $3.91M | $1.63M | $1.85M | $2.97M |
| Gross Profit | $3.00M | $1.97M | $2.23M | $2.03M |
| Gross Profit Ratio | $0.43 | $0.55 | $0.55 | $0.41 |
| R&D Expenses | $156000.00 | $157000.00 | $163000.00 | $170000.00 |
| SG&A Expenses | $2.74M | $2.67M | $2.81M | $2.59M |
| Operating Expenses | $3.26M | $3.14M | $3.28M | $2.76M |
| Total Costs & Expenses | $7.17M | $4.77M | $5.13M | $5.73M |
| Interest Income | $134000.00 | $111000.00 | $117000.00 | $134000.00 |
| Interest Expense | $15000.00 | $15000.00 | $17000.00 | $18000.00 |
| Depreciation & Amortization | $365000.00 | $312000.00 | $304000.00 | $385000.00 |
| EBITDA | $248000.00 | -$709000.00 | -$607000.00 | -$214000.00 |
| EBITDA Ratio | $0.04 | -$0.20 | -$0.15 | -$0.04 |
| Operating Income | -$268000.00 | -$1.17M | -$1.04M | -$731000.00 |
| Operating Income Ratio | -$0.04 | -$0.33 | -$0.26 | -$0.15 |
| Other Income/Expenses (Net) | $92000.00 | $136000.00 | $116000.00 | $105000.00 |
| Income Before Tax | -$176000.00 | -$1.04M | -$928000.00 | -$617000.00 |
| Income Before Tax Ratio | -$0.03 | -$0.29 | -$0.23 | -$0.12 |
| Income Tax Expense | -$14000.00 | $0.00 | -$2000.00 | $9000.00 |
| Net Income | -$162000.00 | -$1.04M | -$926000.00 | -$626000.00 |
| Net Income Ratio | -$0.02 | -$0.29 | -$0.23 | -$0.13 |
| EPS | -$0.008 | -$0.05 | -$0.05 | -$0.03 |
| Diluted EPS | -$0.008 | -$0.05 | -$0.05 | -$0.03 |
| Weighted Avg Shares Outstanding | $19.12M | $19.27M | $19.44M | $19.59M |
| Weighted Avg Shares Outstanding (Diluted) | $19.12M | $19.27M | $19.44M | $19.59M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan